Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors in People With Diabetes and Dyslipidaemia

Diabetes, Obesity and Metabolism - United Kingdom
doi 10.1111/dom.13636
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Clinical Research in Cardiology Supplements
Nuclear MedicineRadiologyMolecular BiologyStructural BiologyImagingMedicine
2019English

Lipoprotein(a) and Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Cost Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 (PCSK9) Inhibitors

Cardiovascular Disorders and Medicine
2019English

Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK-9) Inhibitors Induced Liver Injury - A Retrospective Analysis

Journal of Community Hospital Internal Medicine Perspectives
Internal Medicine
2020English

PCSK6 (Proprotein Convertase Subtilisin/Kexin Type 6)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2017English

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke

Circulation. Genomic and precision medicine
GeneticsCardiovascular MedicineCardiology
2018English

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9

Pharmacological Reviews
Molecular MedicinePharmacology
2016English

Management of Patients Eligible for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Economic Impact and Reform Proposals

Global and Regional Health Technology Assessment
Health Policy
2019English

Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Do We Have a Vanquishing New Strategy?

European Journal of Preventive Cardiology
EpidemiologyCardiovascular MedicineCardiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy